Buy: Cheap Biotech Stocks To

: Working on targeted radiotherapy; analysts project significant revenue growth in 2025-2026 if Phase 3 trials succeed. Undervalued Mid-to-Large Cap Leaders

These companies are considered "cheap" due to low price-to-earnings (P/E) ratios relative to their historical averages or the broader sector. cheap biotech stocks to buy

: Focused on oncology with a high-performing lead drug, Cabometyx, and an estimated three-year revenue CAGR of 11.6%. : Recently transitioned to a commercial-stage firm with

: Recently transitioned to a commercial-stage firm with an FDA-approved cancer drug; analysts see significant upside potential in 2026. Key 2026 Catalysts to Watch Best Biotech Stocks

: A high-risk, high-reward mRNA play with major Phase 2 study results for cystic fibrosis expected in the first half of 2026.

: Analysts view the stock as undervalued, underestimating its core business stability and growth from new product sales. Key 2026 Catalysts to Watch Best Biotech Stocks to Buy for April 2026